494 related articles for article (PubMed ID: 18555033)
21. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
[TBL] [Abstract][Full Text] [Related]
22. Dual time point positron emission tomography/computed tomography scan in evaluation of intrathoracic lesions in an area endemic for histoplasmosis and with high prevalence of sarcoidosis.
Kadaria D; Archie DS; SultanAli I; Weiman DS; Freire AX; Zaman MK
Am J Med Sci; 2013 Nov; 346(5):358-62. PubMed ID: 23276900
[TBL] [Abstract][Full Text] [Related]
23. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
24. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
25. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.
Kumar R; Loving VA; Chauhan A; Zhuang H; Mitchell S; Alavi A
J Nucl Med; 2005 Nov; 46(11):1819-24. PubMed ID: 16269595
[TBL] [Abstract][Full Text] [Related]
26. [Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax].
Zhang TM; Zhang LM; Liu Y; Zhang ZF; Wang CL
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2901-4. PubMed ID: 23328236
[TBL] [Abstract][Full Text] [Related]
27. Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum.
Britz-Cunningham SH; Millstine JW; Gerbaudo VH
Clin Nucl Med; 2008 Oct; 33(10):681-7. PubMed ID: 18806567
[TBL] [Abstract][Full Text] [Related]
28. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
30. Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer.
An YS; Sheen SS; Oh YJ; Hwang SC; Yoon JK
Ann Nucl Med; 2007 Dec; 21(10):585-92. PubMed ID: 18092135
[TBL] [Abstract][Full Text] [Related]
31. Clinical evaluation of PET image reconstruction using a spatial resolution model.
Andersen FL; Klausen TL; Loft A; Beyer T; Holm S
Eur J Radiol; 2013 May; 82(5):862-9. PubMed ID: 23254158
[TBL] [Abstract][Full Text] [Related]
32. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
33. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
34. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
35. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
Shinya T; Rai K; Okumura Y; Fujiwara K; Matsuo K; Yonei T; Sato T; Watanabe K; Kawai H; Sato S; Kanazawa S
Clin Nucl Med; 2009 Apr; 34(4):216-21. PubMed ID: 19300050
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.
Kim BS; Kim IJ; Kim SJ; Pak K; Kim K
Onkologie; 2011; 34(6):298-303. PubMed ID: 21625182
[TBL] [Abstract][Full Text] [Related]
37. The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.
Choi EK; Yoo IeR; Kim SH; O JH; Choi WH; Na SJ; Park SY
Clin Nucl Med; 2013 Mar; 38(3):e106-11. PubMed ID: 23354026
[TBL] [Abstract][Full Text] [Related]
38. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.
Mavi A; Urhan M; Yu JQ; Zhuang H; Houseni M; Cermik TF; Thiruvenkatasamy D; Czerniecki B; Schnall M; Alavi A
J Nucl Med; 2006 Sep; 47(9):1440-6. PubMed ID: 16954551
[TBL] [Abstract][Full Text] [Related]
39. Dual-time-point 18F-FDG PET/CT versus dynamic breast MRI of suspicious breast lesions.
Imbriaco M; Caprio MG; Limite G; Pace L; De Falco T; Capuano E; Salvatore M
AJR Am J Roentgenol; 2008 Nov; 191(5):1323-30. PubMed ID: 18941064
[TBL] [Abstract][Full Text] [Related]
40. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ
Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
